PI3Kα Inhibitor Compounds for Mutant-Selective Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PI3K inhibitors face challenges such as adaptive molecular mechanisms, inability to specifically target PIK3CA mutations, dose-limiting toxicities, and compensatory pathways, limiting their effectiveness in treating cancers with PI3Kα activation.
Innovation Solution
Development of compounds of Formula (I) and (II) that selectively inhibit PI3Kα, addressing the limitations of existing PI3K inhibitors by targeting the PI3K pathway in cancer cells while minimizing toxicity to normal tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current PI3K inhibitors are used to treat cancer, then PI3K pathway suppression is achieved, but dose-limiting toxicities occur that prevent sustained therapy
Solution Approach 1:
The patent applies local quality by designing compounds that selectively inhibit mutant PI3Kα (e.g., E542K, E545K, H1047R) while sparing wild-type PI3Kα. This is achieved through molecular structures that exploit conformational differences between mutant and wild-type enzymes, allowing targeted suppression of cancer cell proliferation without causing systemic toxicities associated with broad PI3K inhibition.
Solution Approach 2:
The patent employs parameter changes by modifying compound structures to alter binding affinity and selectivity profiles. The compounds are designed with specific molecular parameters (substituent groups, ring structures, stereochemistry) that tune their interaction with mutant versus wild-type PI3Kα, enabling effective cancer cell inhibition at doses that do not cause dose-limiting toxicities in normal tissues.
2Productivity
If PI3K inhibitors are administered to suppress tumor growth, then cancer cell death is induced, but adaptive molecular mechanisms develop that reduce therapy effectiveness
Solution Approach 1:
The patent applies preliminary action by using compounds that pre-emptively target multiple compensatory pathways or create initial selective pressure that prevents adaptive resistance. The compounds are designed to inhibit mutant PI3Kα with such high selectivity and potency that they eliminate cancer cells before adaptive mechanisms can develop, or they simultaneously target upstream/downstream pathways to block potential escape routes.
3Reliability
If wild-type PI3Kα is inhibited along with mutant PI3Kα, then cancer cell death is achieved, but toxicity to normal tissues increases
Solution Approach 1:
The patent applies local quality by designing compounds with differential binding characteristics that exploit structural differences between mutant and wild-type PI3Kα. The molecular structures are optimized to form specific interactions with mutant enzyme conformations while having reduced affinity for wild-type, thereby achieving cancer cell selectivity and minimizing toxicity to normal tissues that rely on wild-type PI3Kα function.
Data Source
AI summary
This disclosure provides compounds of Formula (I), Formula (II), and pharmaceutically acceptable salts thereof, that inhibit phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) isoform alpha (PI3Kα). These chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) PI3Kα activation contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also provides compositions containing the same as well as methods of using and making the same.